Ceftriaxone, although less active than standard antistaphylococcal agents, is potentially useful in the treatment of osteomyelitis. Thirty-one patients with osteomyelitis due to Staphylococcus aureus were identified, 22 of whom were treated with ceftriaxone and 9 with other agents. Of those patients treated with ceftriaxone, 17 were cured; all treatment failures were associated with chronic osteomyelitis and continued presence of necrotic bone or infected hardware. It is concluded that ceftriaxone is effective in the ambulatory treatment of S. aureus osteomyelitis.
Intravenous antimicrobial treatment of staphylococcal osteomyelitis increasingly takes place in the ambulatory care setting [1] . Ceftriaxone, which has long pharmacological half-life [2] , may have utility as once-daily treatment for osteomyelitis. However, it is less potent than established antimicrobials such as cefazolin [3] . Furthermore, its high level of protein binding [4] can result in subtherapeutic, free, microbiologically active serum levels. We investigated the efficacy of ceftriaxone as home-care therapy for Staphylococcus aureus osteomyelitis.
Patients and Methods
We screened all patients hospitalized during 1991-1996 with an International Classification of Disease (9th revision)-coded diagnosis of S. aureus osteomyelitis (figure 1). Excluding those patients with infections due to methicillin-resistant S. aureus or other organisms, we identified a cohort of 31 patients at the Medical Center at the University of California San Francisco. All received iv therapy for a minimum of 6 weeks, which included 1-2 weeks of nafcillin, cefazolin, or vancomycin prior to discharge from the hospital. Twenty-two patients were treated with ceftriaxone, 2 g once daily, and 9 with other agents (all doses are currently provided in table 2). MICs for cefazolin and nafcillin were р0.5 mg/mL, and MIC for vancomycin was р1.0 mg/mL. The mean duration of was days. All patients were followed up for therapy ‫ע‬ SD 49 ‫ע‬ 7 a minimum of 6 months.
Definitions. Clinical cure was defined as complete resolution of all signs and symptoms confirmed by microbiological examination. Indeterminate outcome was defined as resolution of signs and symptoms with continuation of suppressive antimicrobial therapy. Treatment failure was defined as continued inflammation with persistent infection or superinfection requiring further surgical and/ or antibiotic therapy. Acute osteomyelitis was defined as newly recognized bone infection; chronic disease was defined as a relapse of a previous treated or untreated infection [5] .
Statistical analyses. Patients who received ceftriaxone were compared with those who received standard antistaphylococcal therapy (cefazolin, vancomycin). No patient received long-term nafcillin. All patients received 1-2 weeks of nafcillin or cefazolin or vancomycin prior to discharge from the hospital. Categorical variables were evaluated with the Fisher's exact test; continuous variables were compared by use of the Student's t test. was P ! .05 considered significant. Tables 1 and 2 show the treatment outcomes for those patients who received ceftriaxone or other standard antistaphylococcal therapies. Of the 22 patients who received ceftriaxone, 17 were considered cured. All of them had native bone osteomyelitis or had had infected prostheses removed at the initiation of antimicrobial therapy. The outcomes for 2 patients were considered indeterminate; in these instances, infected hardware could not be removed and oral antimicrobials were administered. The 3 patients for whom ceftriaxone treatment failed had necrotic bone that could not be surgically excised. Although diarrhea and biliary tract symptoms have been described as common adverse effects associated with ceftriaxone therapy [6] , they were not documented for any of the patients. Of those patients who received cefazolin or vancomycin, 7
Results
were considered cured, 1 had an indeterminate outcome, and the treatment for 1 failed. The 1 patient for whom treatment (vancomycin) failed had spinal osteomyelitis and infected hardware that could not be removed.
Discussion
Although ceftriaxone has been suggested as a possible therapy for S. aureus osteomyelitis, clinicians have been reluctant to use it. It is less potent against S. aureus than are other agents; for example, the MIC 90 for ceftriaxone is 2 mg/mL, whereas it is 0.5 mg/mL for cefazolin. An additional concern is ceftriaxone's moderate-to-high level of protein binding (85%-95%) [4] . It is a free antimicrobial that is microbiologically active [7] , and free levels of b-lactams should remain above the MIC for most of the dosing interval [8] . Previously published reports suggest that treatment of serious staphylococcal infection with highly protein-bound cephalosporins is associated with clinical failure [9] . Normal-sized patients who received ceftriaxone, 2 g daily, have documented trough levels of 10-50 mg/mL [2] , assuming unbound ceftriaxone to be ∼10% of the total results in estimated free trough levels at 1-5 mg/mL [4] . Consequently, free microbiologically active levels remain above the MIC for most if not all of the dosing interval.
In summary, we report the largest series of cases of S. aureus osteomyelitis treated with once-a-day ceftriaxone therapy. Our findings suggest that ceftriaxone, similar to other more established antistaphylococcal regimens, is effective in the treatment of this serious infection. However, the documented treatment failures reinforce the importance of surgical excision of infected hardware or necrotic bone. The documented efficacy and safety of ceftriaxone, coupled with the convenience of its once-daily administration, suggest that it could be useful as therapy for S. aureus osteomyelitis.
